MedTrace Logo

Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)

NCT06008249 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-05-13

No results posted yet for this study

Summary

The objective of this phase III, placebo-controlled platform study is to investigate the efficacy of drugs for patients with ALS (Amyotrophic lateral sclerosis).

Conditions

Interventions

DRUG

Lithium Carbonate 400 MG

Lithium carbonate vs placebo (2:1)

Sponsors & Collaborators

  • Fight MND

    collaborator UNKNOWN

  • Research Foundation Flanders

    collaborator OTHER

  • MNDA

    collaborator UNKNOWN

  • Thierry Latran Foundation

    collaborator UNKNOWN

  • Ulla-Carin Lindquist Foundation

    collaborator UNKNOWN

  • Luzon Foundation

    collaborator UNKNOWN

  • Alan Davidson Foundation

    collaborator UNKNOWN

  • My name'5 Doddie Foundation

    collaborator UNKNOWN

  • Stichting ALS Nederland

    collaborator UNKNOWN

  • Stichting TRICALS Foundation

    lead OTHER

Principal Investigators

  • Leonard Van den Berg, MD · TRICALS Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2025-09-01
Completion
2025-09-01

Countries

  • Australia
  • Belgium
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008249 on ClinicalTrials.gov